270 related articles for article (PubMed ID: 31871115)
1. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Mayadev J; Zamarin D; Deng W; Lankes H; O'Cearbhaill R; Aghajanian CA; Schilder R
Int J Gynecol Cancer; 2020 May; 30(5):701-704. PubMed ID: 31871115
[TBL] [Abstract][Full Text] [Related]
2. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
[TBL] [Abstract][Full Text] [Related]
3. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
Liu C; Ran X; Wang Z; Zhang K
Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
[TBL] [Abstract][Full Text] [Related]
6. PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study.
Martinez A; Lecuru F; Bizzarri N; Chargari C; Ducassou A; Fagotti A; Fanfani F; Scambia G; Cibula D; Díaz-Feijoo B; Gil Moreno A; Angeles MA; Muallem MZ; Kohler C; Luyckx M; Kridelka F; Rychlik A; Gerestein KG; Heinzelmann V; Ramirez PT; Frumovitz M; Ferron G; Betrian S; Filleron T; Fotopoulou C; Querleu D;
Int J Gynecol Cancer; 2023 Feb; 33(2):293-298. PubMed ID: 36717163
[TBL] [Abstract][Full Text] [Related]
7. Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial.
Köhler C; Mustea A; Marnitz S; Schneider A; Chiantera V; Ulrich U; Scharf JP; Martus P; Vieira MA; Tsunoda A
Am J Obstet Gynecol; 2015 Oct; 213(4):503.e1-7. PubMed ID: 25986030
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer.
Brockbank E; Kokka F; Bryant A; Pomel C; Reynolds K
Cochrane Database Syst Rev; 2011 Apr; (4):CD008217. PubMed ID: 21491407
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study.
Tu H; Huang H; Ouyang Y; Liu Q; Xian B; Song K; Chen G; Shen Y; Liu J
Int J Gynecol Cancer; 2021 Jan; 31(1):129-133. PubMed ID: 32522771
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma - a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience.
Green HM; Counsell N; Ward A; McCormack M
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e281-e290. PubMed ID: 35000828
[TBL] [Abstract][Full Text] [Related]
11. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation.
Garcia-Duran C; Grau F; Villacampa G; Oaknin A
Int J Gynecol Cancer; 2022 Apr; ():. PubMed ID: 35444013
[TBL] [Abstract][Full Text] [Related]
12. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
[TBL] [Abstract][Full Text] [Related]
13. Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX cancer).
Dostalek L; Runnebaum I; Raspagliesi F; Vergote I; Dusek L; Jarkovsky J; Cibula D
Int J Gynecol Cancer; 2020 Feb; 30(2):261-264. PubMed ID: 31748245
[TBL] [Abstract][Full Text] [Related]
14. Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.
Del Carmen MG; Pareja R; Melamed A; Rodriguez J; Greer A; Clark RM; Rice LW
Gynecol Oncol; 2018 Sep; 150(3):406-411. PubMed ID: 30017539
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of lymph node dissection on stage IIICr of cervical cancer before CCRT: study protocol for a phase III, randomized controlled clinical trial (CQGOG0103).
He M; Guo M; Zhou Q; Tang Y; Zhong L; Liu Q; Fan X; Zhao X; Zhang X; Chen G; Shen Y; Xu Q; Chen X; Li Y; Zou D
J Gynecol Oncol; 2023 May; 34(3):e55. PubMed ID: 36998225
[TBL] [Abstract][Full Text] [Related]
16. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
17. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
18. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
[TBL] [Abstract][Full Text] [Related]
19. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
Okonogi N; Usui H; Murata K; Hori M; Kurokawa T; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Hasegawa S; Yamada S; Hanaoka H; Shozu M; Tsuji H
BMJ Open; 2022 Mar; 12(3):e056424. PubMed ID: 35236732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
